GlassScriptPhysician profile
William L Mchenry
NPI 1295728152
$688.16
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2022: $17.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $222.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.90 | 2019 | |
| Novo Nordisk INC | $92.28 | 2019 | |
| Astellas Pharma US INC | $69.04 | 2019 | |
| Amarin Pharma, INC. | $44.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.95 | 2019 | |
| Allergan, INC. | $25.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.74 | 2019 | |
| Glaxosmithkline, LLC. | $17.68 | 2019 | |
| Pfizer INC. | $17.55 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mchenry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.